Geneos Wealth Management Inc. Incyte Corp Transaction History

Geneos Wealth Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 18, 2025	BUY	$55.17 - $71.22 $3,089 - $3,988	56 Added 7.41%	812 $55,000
Q1 2025 May 21, 2025	SELL	$60.0 - $75.26 $12,360 - $15,503	-206 Reduced 21.41%	756 $45,000
Q1 2025 May 07, 2025	BUY	$60.0 - $75.26 $47,640 - $59,756	794 Added 472.62%	962 $58,000
Q4 2024 Jan 21, 2025	BUY	$65.08 - $83.38 $3,644 - $4,669	56 Added 50.0%	168 $11,000
Q3 2024 Nov 14, 2024	BUY	$57.33 - $68.61 $6,420 - $7,684	112 New	112 $7,000

Q1 2020 Sep 07, 2021	SELL	$63.18 - $85.97 $6,318 - $8,597	-100 Closed	0 $0
Q4 2019 Sep 07, 2021	BUY	$73.04 - $95.72 $7,304 - $9,572	100 New	100 $8,000
Q2 2017 Sep 07, 2021	SELL	N/A	-9 Closed	0 $0
Q1 2017 Sep 07, 2021	SELL	N/A	-16 Reduced 64.0%	9 $1,000
Q3 2016 Sep 07, 2021	BUY	N/A	25	25 $2,000

818

205M

638K

635K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $23.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

Stay updated on Geneos Wealth Management Inc. with notifications on news.